New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
07:31 EDTTXMDTherapeuticsMD receives notice of allowance for patent
TherapeuticsMD received a Notice of Allowance from the U.S. Patent and Trademark Office pertaining to its U.S. Patent Application 13/684,002 - "Natural Combination Hormone Replacement Formulations and Therapies." This Patent Application covers the company’s platform technology TX 12-001-HR, its oral bioidentical 17β-estradiol and progesterone combination drug candidate. Robert Finizio, CEO and Co-founder of TherapeuticsMD, says "Based on clinical data presented earlier this year, we believe TX 12-001-HR has overcome these hurdles and that this novel combination of 17ß- estradiol and progesterone may achieve equivalent efficacy with better bioavailability as compared to current hormone therapies. We eagerly await the outcomes of the ongoing REPLENISH Trial."
News For TXMD From The Last 14 Days
Check below for free stories on TXMD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
07:22 EDTTXMDBiotech Industry Organization to hold a conference
Subscribe for More Information
April 7, 2014
16:10 EDTTXMDTherapeuticsMD reports positive outcomes for TX 004-HR study
Subscribe for More Information
07:30 EDTTXMDTherapeuticsMD launches Prena1 Pearl
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use